<DOC>
	<DOCNO>NCT01323959</DOCNO>
	<brief_summary>This study evaluate persistence immune response diphtheria , tetanus , pertussis poliomyelitis healthy adult , 10 year booster dose , also assess immunogenicity safety another booster dose BoostrixTM Polio .</brief_summary>
	<brief_title>Immunogenicity Safety Booster Dose BoostrixTM Polio Vaccine Previously Boosted Adults</brief_title>
	<detailed_description>This protocol post update follow protocol amendment 1 , date 03 June 2011 . The impacted section : Eligibility Criteria ( Exclusion criterion ) .</detailed_description>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Male female subject receive vaccine study NCT01277705 . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study receive booster vaccine , subject : practices/has practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire booster epoch . Use investigational nonregistered product study vaccine within 30 day precede booster dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior booster dose . Administration vaccine foreseen study protocol within 30 day prior booster vaccination , plan administration active study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . History reaction hypersensitivity likely exacerbate component vaccine . Previous booster vaccination diphtheria , tetanus , pertussis poliovirus since dose receive study NCT01277705 . In Germany , previous dose monovalent vaccine pertussis allow subject Group C. History diphtheria , tetanus , pertussis poliomyelitis diseases follow receipt booster dose study NCT01277705 . Any confirm suspected immunosuppressive immunodeficiency condition base medical history physical examination . Occurrence transient thrombocytopenia neurological complication follow early immunisation diphtheria and/or tetanus . Occurrence follow adverse event previous administration DTP vaccine : Hypersensitivity reaction component vaccine , encephalopathy unknown aetiology occur within seven day follow previous vaccination pertussiscontaining vaccine , fever ≥ 40°C within 48 hour vaccination due another identifiable cause , collapse shocklike state within 48 hour vaccination , convulsion without fever , occur within 3 day vaccination . Administration immunoglobulins and/or blood product within three month precede booster dose plan administration study period . Acute disease and/or fever time enrolment . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>BoostrixTM Polio</keyword>
	<keyword>dTpa-IPV</keyword>
	<keyword>booster</keyword>
</DOC>